Study guide
17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal
Professional and Linguistic Assessments Board Part 1 PLAB 1
Track your progress as you read
Finished sections get a check mark.
1 Introduction
About the PLAB 1 Exam
2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies
1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies
3 Chapter 2: Cardiovascular Medicine & Vascular Disorders
2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease
4 Chapter 3: Respiratory Medicine
3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure
5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery
4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD
6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance
5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies
7 Chapter 6: Endocrinology & Metabolic Medicine
6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease
8 Chapter 7: Neurology & Neurosciences
7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders
9 Chapter 8: Psychiatry & Mental Health
8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health
10 Chapter 9: Obstetrics, Gynaecology & Sexual Health
9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence
11 Chapter 10: Paediatrics & Child Health
10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems
12 Chapter 11: Musculoskeletal Medicine & Rheumatology
11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders
13 Chapter 12: Dermatology, ENT & Ophthalmology
12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer
14 Chapter 13: Haematology, Oncology & Palliative Care
13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral
15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology
14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship
16 Chapter 15: Medical Ethics, Law & UK Clinical Practice
15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse
17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention
16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention
18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging
17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays
17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal
Key Takeaways Explain This Topic AI
Sensitivity is the proportion of people with the disease who test positive (TP/(TP+FN)); specificity is the proportion without the disease who test negative (TN/(TN+FP)).
Positive and negative predictive values depend on disease prevalence, whereas sensitivity and specificity are properties of the test itself.
The number needed to treat is 1 divided by the absolute risk reduction (the control event rate minus the experimental event rate).
Case-control studies compare exposures in cases and controls and report odds ratios, while cohort studies follow exposed and unexposed groups and report relative risks.
A 95% confidence interval for a relative risk or odds ratio that includes 1 (or for a difference that includes 0) indicates a result that is not statistically significant at the 5% level.
Last updated: October 2026
- Medical Statistics, Diagnostic Tests & Critical Appraisal
- Diagnostic Test Accuracy
Use a 2 x 2 table comparing the test with a reference standard:
- Disease Present Disease Absent
- Test Positive True positive (TP) False positive (FP)
- Test Negative False negative (FN) True negative (TN)
- Measure Formula Meaning
- Sensitivity TP / (TP + FN) Proportion of people with the disease who test positive
- Specificity TN / (TN + FP) Proportion of people without the disease who test negative
- Positive predictive value (PPV) TP / (TP + FP) Probability that a positive result is a true positive
- Negative predictive value (NPV) TN / (TN + FN) Probability that a negative result is a true negative
Positive likelihood ratio Sensitivity / (1 − specificity) How much a positive result increases the odds of disease
Negative likelihood ratio (1 − sensitivity) / specificity How much a negative result decreases the odds of disease
Sensitivity and specificity are properties of the test ; predictive values change with prevalence . In a low-prevalence population (screening), even a specific test produces many false positives, so the PPV falls.
SnNout: a highly sensitive test, when negative , rules a condition out (for example D-dimer for low-probability VTE). SpPin: a highly specific test, when positive , rules a condition in .
Measures of Risk & Treatment Effect
Using the control event rate ( CER ) and experimental event rate ( EER ):
- Measure Formula
- Absolute risk reduction (ARR) CER − EER
- Relative risk (RR) EER / CER
- Relative risk reduction (RRR) (CER − EER) / CER, or 1 − RR
- Number needed to treat (NNT) 1 / ARR (round up to a whole number)
- Number needed to harm (NNH) 1 / absolute risk increase of an adverse effect
Worked example: a stroke occurs in 10% of the control group and 6% of the treated group. ARR = 0.10 − 0.06 = 0.04 ; RR = 0.06 / 0.10 = 0.6 ; RRR = 40% ; NNT = 1 / 0.04 = 25 . Relative risk reductions sound impressive; absolute figures and NNT help patients understand benefit.
Odds ratio (OR): odds of exposure in cases divided by odds in controls; used in case-control studies and logistic regression; approximates the relative risk when the outcome is rare.
Hazard ratio: the relative rate of an event over time in survival analysis.
Incidence is the number of new cases in a population over a period; prevalence is the proportion with the condition at a point in time (prevalence is roughly incidence multiplied by average duration).
Study Designs & the Hierarchy of Evidence
Design Description Strengths & Weaknesses
Systematic review and meta-analysis Combines all relevant studies; results shown in a forest plot Highest level if good-quality trials; heterogeneity and publication bias (funnel plot asymmetry) are problems
Randomised controlled trial (RCT) Random allocation to intervention or control Best design for treatment effects; randomisation balances known and unknown confounders; allocation concealment , blinding and intention-to-treat analysis reduce bias
Cohort study Follows exposed and unexposed groups forward in time Measures incidence and relative risk ; good for rare exposures and multiple outcomes; slow and costly; loss to follow-up
Case-control study Compares past exposures in people with a disease (cases) and without (controls) Quick, good for rare diseases ; gives odds ratios ; prone to recall and selection bias
Cross-sectional survey Measures exposure and outcome at one time Measures prevalence ; cannot show cause and effect
- Case series / case report Descriptions of patients Generate hypotheses only
- Ecological study Compares populations rather than individuals Risk of the ecological fallacy
Phases of drug trials: phase I (safety, dose, often healthy volunteers), phase II (efficacy and side effects in patients), phase III (large comparative RCTs before licensing), phase IV (post-marketing surveillance, including Yellow Card reporting).
Bias, Confounding & Screening Pitfalls
Selection bias: the study population does not represent the target population.
Information (measurement) bias: recall bias, observer bias, misclassification.
Confounding: a third factor linked to both exposure and outcome (for example smoking confounding an association between coffee and lung cancer). Control it by randomisation , restriction, matching, stratification or multivariable analysis.
Screening biases: lead-time bias (earlier diagnosis seems to lengthen survival without changing the time of death), length-time bias (screening preferentially detects slow-growing disease) and overdiagnosis.
Statistical Significance & Errors
p-value: the probability of results at least as extreme as those observed if the null hypothesis were true; p below 0.05 is conventionally "significant". It does not measure the size or importance of an effect.
95% confidence interval: the range likely to contain the true value. For a ratio (RR, OR, HR) , an interval including 1 is not significant; for a difference , an interval including 0 is not significant. Narrow intervals mean more precise estimates.
Type I error (alpha): a false positive , rejecting a true null hypothesis (usually set at 5%).
Type II error (beta): a false negative , failing to detect a real effect; power = 1 − beta (usually 80–90%) and increases with sample size and effect size.
Choosing a Statistical Test
Data Two Independent Groups Paired Data Association
Continuous, normally distributed Unpaired (Student's) t-test; ANOVA for 3 or more groups Paired t-test Pearson's correlation
- Continuous non-normal or ordinal Mann-Whitney U test Wilcoxon signed-rank test Spearman's rank correlation
- Categorical (proportions) Chi-squared test (Fisher's exact test for small numbers) McNemar's test Chi-squared
- Distributions
Normal distribution: symmetrical; mean = median = mode; about 68% of values lie within 1 standard deviation, 95% within about 2 SD and 99.7% within 3 SD.
Positive (right) skew: a long tail to the right; mean > median > mode . Negative skew: mean < median < mode. Use the median and interquartile range for skewed data.
Standard deviation describes the spread of the data; the standard error of the mean (SD divided by the square root of n) describes the precision of the mean estimate.
Loading diagram...